Charleston, SC -- (SBWIRE) -- 09/20/2013 -- Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s Penny Stocks issues news updates on the following stock: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Cintas Corp. (NASDAQ:CTAS).
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel" or the "Company") on Friday declared updated data indicating that sapacitabine has activity against a greater part of ovarian cancer samples received from patients, consisting of resistant tumors.
The data were declared at a poster presentation in the American Association of Cancer Research (AACR) conference “Advances in Ovarian Cancer: from concept to clinic" being kept on September 18-21, 2013, in Miami, FL.
Can Investors Bet on CYCC after this News update? Find out in this Research Report
We are motivated by the activity indication of sapacitabine in ovarian cancer samples, Judy Chiao reported, M.D., Vice President, Clinical Development and Regulatory Affairs of Cyclacel.
This surveillancemight be directly associated to the drug's mechanism which is improved in cancer cells with lowered capacity for DNA repair through the homologous recombination repair or HR pathway.
How Should Investors Trade CYCC Now? Don’t Miss out a Special Trend Analysis
Cintas Corp. (NASDAQ:CTAS) reported that its fiscal first-quarter earnings jumped up 1.3% as the provider of uniforms and restroom supplies reported superior revenue amid lesser margins.
Shares of Cintas were higher 4.2% at $53 in after-hours trading as the firm lifted its complete year earnings outlook.
Cintas lifted its per-share earnings target for the fiscal year by four cents on each end to $2.70 to $2.79 to mirror the impact of share repurchasing so far in the fiscal year. The firm reported that it bought back three million common shares at a cost of almost $147 million.
What CTAS’s Charts Are Signaling for Traders? Find Out Here
About Today’s Penny Stocks
Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s wants you to do your own due diligence on your investments please use our site to find the information you need on whichever investment you choose.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the TodaysPennyStocks.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
TodaysPennyStocks.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Read Full Disclaimer at: http://todayspennystocks.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)